Contact
Please use this form to send email to PR contact of this press release:
XELSTRYMâ„¢ (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professional Society of ADHD and Related Disorders (APSARD) Conference
TO: